ARS Pharmaceuticals (SPRY) Competitors

$8.01 -0.62 (-7.18%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$8.05 +0.04 (+0.52%)

As of 08:53 AM Eastern

SPRY vs. BEAM, TNGX, ORKA, RCUS, and ERAS

Should you buy ARS Pharmaceuticals stock or one of its competitors? MarketBeat compares ARS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ARS Pharmaceuticals include Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), Oruka Therapeutics (ORKA), Arcus Biosciences (RCUS), and Erasca (ERAS). These companies are all part of the "pharmaceutical products" industry.

How does ARS Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

In the previous week, Beam Therapeutics had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 11 mentions for Beam Therapeutics and 6 mentions for ARS Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.72 beat ARS Pharmaceuticals' score of 0.64 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a net margin of -39.66% compared to ARS Pharmaceuticals' net margin of -203.25%. Beam Therapeutics' return on equity of -29.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%

Beam Therapeutics currently has a consensus target price of $46.83, indicating a potential upside of 47.04%. ARS Pharmaceuticals has a consensus target price of $28.25, indicating a potential upside of 252.68%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Beam Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Beam Therapeutics has higher revenue and earnings than ARS Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	23.45	-$79.99M	-$0.68	N/A
ARS Pharmaceuticals	$84.28M	9.44	-$171.30M	-$1.75	N/A

Summary

Beam Therapeutics beats ARS Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Tango Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Tango Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	58.99	-$101.59M	-$0.87	N/A
ARS Pharmaceuticals	$84.28M	9.44	-$171.30M	-$1.75	N/A

Tango Therapeutics presently has a consensus target price of $22.44, suggesting a potential downside of 12.02%. ARS Pharmaceuticals has a consensus target price of $28.25, suggesting a potential upside of 252.68%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Tango Therapeutics and Tango Therapeutics both had 6 articles in the media. Tango Therapeutics' average media sentiment score of 0.86 beat ARS Pharmaceuticals' score of 0.64 indicating that Tango Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 6.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Tango Therapeutics has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Tango Therapeutics has a net margin of -151.15% compared to ARS Pharmaceuticals' net margin of -203.25%. Tango Therapeutics' return on equity of -50.30% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-50.30%	-36.25%
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%

Summary

Tango Therapeutics beats ARS Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

Oruka Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Oruka Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.86	N/A
ARS Pharmaceuticals	$84.28M	9.44	-$171.30M	-$1.75	N/A

Oruka Therapeutics presently has a consensus target price of $120.80, indicating a potential upside of 91.20%. ARS Pharmaceuticals has a consensus target price of $28.25, indicating a potential upside of 252.68%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Oruka Therapeutics had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 11 mentions for Oruka Therapeutics and 6 mentions for ARS Pharmaceuticals. Oruka Therapeutics' average media sentiment score of 1.16 beat ARS Pharmaceuticals' score of 0.64 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oruka Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oruka Therapeutics has a beta of -0.2, suggesting that its share price is 120% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Oruka Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -203.25%. Oruka Therapeutics' return on equity of -25.48% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-25.48%	-24.34%
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%

Summary

Oruka Therapeutics beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Arcus Biosciences?

ARS Pharmaceuticals (NASDAQ:SPRY) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Arcus Biosciences has a net margin of -156.36% compared to ARS Pharmaceuticals' net margin of -203.25%. Arcus Biosciences' return on equity of -68.97% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

ARS Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.44	-$171.30M	-$1.75	N/A
Arcus Biosciences	$247M	12.74	-$353M	-$3.18	N/A

In the previous week, Arcus Biosciences had 12 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 18 mentions for Arcus Biosciences and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.64 beat Arcus Biosciences' score of 0.27 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcus Biosciences	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

ARS Pharmaceuticals currently has a consensus target price of $28.25, suggesting a potential upside of 252.68%. Arcus Biosciences has a consensus target price of $33.33, suggesting a potential upside of 33.24%. Given ARS Pharmaceuticals' higher probable upside, equities analysts clearly believe ARS Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Arcus Biosciences beats ARS Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Erasca?

ARS Pharmaceuticals (NASDAQ:SPRY) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Erasca had 18 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 24 mentions for Erasca and 6 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.64 beat Erasca's score of 0.10 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Erasca	2 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ARS Pharmaceuticals presently has a consensus price target of $28.25, suggesting a potential upside of 252.68%. Erasca has a consensus price target of $18.75, suggesting a potential upside of 79.25%. Given ARS Pharmaceuticals' higher possible upside, equities analysts plainly believe ARS Pharmaceuticals is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Erasca has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -203.25%. Erasca's return on equity of -35.31% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-203.25%	-100.29%	-51.09%
Erasca	N/A	-35.31%	-29.49%

ARS Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Erasca has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Erasca has lower revenue, but higher earnings than ARS Pharmaceuticals. Erasca is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	9.44	-$171.30M	-$1.75	N/A
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Erasca beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$856.97M	$3.05B	$6.31B	$12.28B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-4.58	18.86	21.03	25.58
Price / Sales	9.44	295.49	552.34	78.22
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	6.91	4.35	9.83	6.66
Net Income	-$171.30M	$72.19M	$3.55B	$333.63M
7 Day Performance	-11.00%	-1.05%	-0.52%	-0.12%
1 Month Performance	-1.60%	-0.02%	1.20%	3.93%
1 Year Performance	-33.80%	46.31%	41.25%	36.07%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	2.9152 of 5 stars	$8.01 -7.2%	$28.25 +252.7%	-40.0%	$856.97M	$84.28M	N/A	90	Upcoming Earnings
BEAM Beam Therapeutics	3.8131 of 5 stars	$31.75 -1.8%	$47.17 +48.6%	+76.5%	$3.33B	$139.74M	N/A	510	Earnings Report Analyst Forecast
TNGX Tango Therapeutics	1.4976 of 5 stars	$23.48 +2.0%	$22.44 -4.4%	+1,722.1%	$3.32B	$62.38M	N/A	90	Earnings Report Analyst Upgrade
ORKA Oruka Therapeutics	3.6227 of 5 stars	$65.68 +1.7%	$120.80 +83.9%	+556.8%	$3.24B	N/A	N/A	N/A	Earnings Report
RCUS Arcus Biosciences	3.3499 of 5 stars	$24.87 -2.0%	$33.33 +34.1%	+188.9%	$3.19B	$247M	N/A	500	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. BEAM, TNGX, ORKA, RCUS, and ERAS

How does ARS Pharmaceuticals compare to Beam Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Tango Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Oruka Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Arcus Biosciences?

Summary

How does ARS Pharmaceuticals compare to Erasca?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. BEAM, TNGX, ORKA, RCUS, and ERAS

How does ARS Pharmaceuticals compare to Beam Therapeutics?

Does the media refer more to BEAM or SPRY?

Is BEAM or SPRY more profitable?

Do analysts recommend BEAM or SPRY?

Which has more volatility & risk, BEAM or SPRY?

Do insiders and institutionals believe in BEAM or SPRY?

Which has stronger valuation and earnings, BEAM or SPRY?

Summary

How does ARS Pharmaceuticals compare to Tango Therapeutics?

Which has stronger earnings & valuation, TNGX or SPRY?

Do analysts rate TNGX or SPRY?

Does the media favor TNGX or SPRY?

Do institutionals & insiders have more ownership in TNGX or SPRY?

Which has more volatility and risk, TNGX or SPRY?

Is TNGX or SPRY more profitable?

Summary

How does ARS Pharmaceuticals compare to Oruka Therapeutics?

Which has better earnings & valuation, ORKA or SPRY?

Do analysts prefer ORKA or SPRY?

Does the media favor ORKA or SPRY?

Do institutionals & insiders have more ownership in ORKA or SPRY?

Which has more risk & volatility, ORKA or SPRY?

Is ORKA or SPRY more profitable?

Summary

How does ARS Pharmaceuticals compare to Arcus Biosciences?

Do insiders and institutionals have more ownership in SPRY or RCUS?

Is SPRY or RCUS more profitable?

Which has stronger valuation & earnings, SPRY or RCUS?

Does the media refer more to SPRY or RCUS?

Which has more volatility & risk, SPRY or RCUS?

Do analysts recommend SPRY or RCUS?

Summary

How does ARS Pharmaceuticals compare to Erasca?

Does the media refer more to SPRY or ERAS?

Do analysts rate SPRY or ERAS?

Is SPRY or ERAS more profitable?

Which has more risk and volatility, SPRY or ERAS?

Which has higher valuation & earnings, SPRY or ERAS?

Do institutionals and insiders have more ownership in SPRY or ERAS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools